Shaun McMeans

Shaun McMeans was appointed to Vaso Corporation's Board of Directors effective July 23, 2026. He currently serves as Chief Financial Officer of Nabsys, a life sciences technology company, where he leads finance and administrative functions. McMeans brings substantial public company finance, accounting and operational leadership experience in the life sciences and technology sectors.

Education

McMeans received a B.S. in Accounting from The Pennsylvania State University.

Career History

• Chief Financial Officer, Nabsys (current)
• Chief Financial Officer, HTG Molecular Diagnostics, Inc. (2012-2023)
• Vice President – Finance of Securaplane Technologies, Inc.
• Financial consultant, Tatum LLC
• Chief Financial Officer, The Long Companies
• Chief Financial and Operating Officer, LXU Healthcare, Inc.
• Finance roles, Burnham Holdings, Inc.

At HTG Molecular Diagnostics, a publicly traded life science tools and diagnostics company, McMeans served as Chief Financial Officer from 2012 through 2023. Earlier, he relocated to Tucson in 2000 and enjoyed a twelve-year career in finance at Burnham Corporation.

What Shaun McMeans could bring to Vaso Corporation Board: Based on his demonstrated career trajectory, McMeans brings deep expertise in navigating publicly traded life sciences and technology companies through complex financial and operational challenges. His tenure managing HTG Molecular Diagnostics' finance during critical growth phases, combined with his current role at Nabsys advancing genomic technology commercialization, positions him to provide valuable perspective on strategic financial planning, capital allocation, and operational optimization as Vaso executes its multi-segment MedTech strategy across IT services, healthcare equipment sales, and proprietary medical devices.